About: Does SARS‐Cov‐2 invade the brain? Translational lessons from animal models

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Does SARS‐Cov‐2 invade the brain? Translational lessons from animal models Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Does SARS‐Cov‐2 invade the brain? Translational lessons from animal models
Creator	Oliveira, V Calabresi, P Maia, L Natoli, S Pisani, A
topic	covid:45aefae4323d7e4191dd08f49876f4ed4b81308e#this
Source	Medline; PMC
abstract	The current coronavirus disease (COVID‐19) outbreak, caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), has raised the possibility of potential neurotropic properties of this virus. Indeed, neurological sequelae of SARS‐CoV‐2 infection have already been reported and highlight the relevance of considering the neurological impact of coronavirus (CoV) from a translational perspective. Animal models of SARS and Middle East respiratory syndrome, caused by structurally similar CoVs during the 2002 and 2012 epidemics, have provided valuable data on nervous system involvement by CoVs and the potential for central nervous system spread of SARS‐CoV‐2. One key finding that may unify these pathogens is that all require angiotensin‐converting enzyme 2 as a cell entry receptor. The CoV spike glycoprotein, by which SARS‐CoV‐2 binds to cell membranes, binds angiotensin‐converting enzyme 2 with a higher affinity compared with SARS‐CoV. The expression of this receptor in neurons and endothelial cells hints that SARS‐CoV‐2 may have higher neuroinvasive potential compared with previous CoVs. However, it remains to be determined how such invasiveness might contribute to respiratory failure or cause direct neurological damage. Both direct and indirect mechanisms may be of relevance. Clinical heterogeneity potentially driven by differential host immune‐mediated responses will require extensive investigation. Development of disease models to anticipate emerging neurological complications and to explore mechanisms of direct or immune‐mediated pathogenicity in the short and medium term is therefore of great importance. In this brief review, we describe the current knowledge from models of previous CoV infections and discuss their potential relevance to COVID‐19.
has issue date	2020-05-22(xsd:dateTime)
bibo:doi	10.1111/ene.14277
bibo:pmid	32333487
has license	no-cc
sha1sum (hex)	45aefae4323d7e4191dd08f49876f4ed4b81308e
schema:url	https://doi.org/10.1111/ene.14277
resource representing a document's title	Does SARS‐Cov‐2 invade the brain? Translational lessons from animal models
has PubMed Central identifier	PMC7267377
has PubMed identifier	32333487
schema:publication	Eur J Neurol
resource representing a document's body	covid:45aefae4323d7e4191dd08f49876f4ed4b81308e#body_text
is http://vocab.deri.ie/void#inDataset of	proxy:http/ns.inria.fr/covid19/45aefae4323d7e4191dd08f49876f4ed4b81308e
is schema:about of	named entity 'RT-qPCR' named entity 'T-cells' named entity 'pre-clinical' named entity 'antibody' named entity 'cerebral veins' named entity 'cytopathic effects' named entity 'infection' named entity 'hematogenous' named entity 'airway epithelia' named entity 'MERS-CoV' named entity 'SARS-CoV-2' named entity 'interstitial pneumonia' named entity 'pathogenicity' named entity 'stem cells' named entity 'SARS-CoV-2' named entity 'lung' named entity 'viral replication' named entity 'virus' named entity 'neurotransmitter' named entity 'Neuropathology' named entity 'ACE2' named entity 'beta-CoV' named entity 'ACE2' named entity 'olfactory nerve' named entity 'RNA polymerase' named entity 'neuroinvasive' named entity 'neurological' named entity 'neurological' named entity 'MERS-CoV' named entity 'Parkinson's disease' named entity 'immune cells' named entity 'SARS' named entity 'DPP4' named entity 'olfactory bulb' named entity 'inflammatory response' named entity 'animal models' named entity 'SARS-CoV' named entity 'SARS-CoV' named entity 'viral infection' named entity 'lungs' named entity 'pathogenicity' named entity 'SARS-CoV-2' named entity 'stroke' named entity 'epithelial' named entity 'neurological diseases' named entity 'interstitial pneumonia' named entity 'tumor necrosis factor alpha' named entity 'COVID-19' named entity 'blood vessels' named entity 'DPP4' named entity 'infection' named entity 'mesylate' named entity 'blood-brain barrier' named entity 'infection' named entity 'brain tissue' named entity 'acute disseminated encephalomyelitis' named entity 'CNS' named entity 'histopathologically' named entity 'infection' named entity 'brain tissue' named entity 'cytokeratin 18' named entity 'angiotensin-converting enzyme 2' named entity 'clinical features' named entity 'brain tissue' named entity 'synapse' named entity 'tropism' named entity 'COVID' named entity 'long-term' named entity 'neurons' named entity 'virus' named entity 'animal models' named entity 'SARS-Cov-2' named entity 'CNS' named entity 'infection' named entity 'pathogen'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software